912846-75-4

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
Tert-butyl 6-amino-7-chloro-3,4-dihydroisoquinoline-2(1H)-carboxylate is used as a building block in the synthesis of potential drug candidates. Its structure and properties make it a valuable component for the creation of new potential medications.
Used in Biological and Pharmacological Studies:
Due to its unique chemical structure and functional groups, tert-butyl 6-amino-7-chloro-3,4-dihydroisoquinoline-2(1H)-carboxylate is used as a target for biological and pharmacological studies, which can lead to the discovery of new therapeutic agents and a better understanding of their mechanisms of action.

Upstream product

• 912846-74-3 tert-butyl 7-chloro-6-nitro-3,4-dihydroisoquinoline-2(1H)-carboxylate 

Relevant academic research and scientific papers

CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF

Biomarkers are provided that are predictive and/or indicative of a subject's responsiveness to a cyclin-dependent kinase 2 (CDK2) inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing a disease or disorder associated with CDK2 and for monitoring treatment.

PYRROLO[2,3-D]PYRIMIDINONE COMPOUNDS AS CDK2 INHIBITORS

The present application provides pyrrolo[2,3-d]pyrimidinone (I) inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

SULFONYLAMIDE COMPOUNDS AS CDK2 INHIBITORS

The present application provides sulfonyl amide compounds of formula (I), which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS

The present invention provides at least one chemical entity chosen from compounds of formula (I) wherein: R1 represents a group selected from formula (II), (III), (IV), (V), (VI), (VII), each ring of which optionally contains a further heteroatom N, Z represents an optional substituent halogen, -C1-3alkyl or -NRaRb, alk represents alkylene or alkenylene, T represents S, O or NH; Ra and Rb independently represent hydrogen or -C1-3alkyl; R2 represents a group selected from formula (VIII), (IX), W, X and Y independently represent CH, C-R5 or N; R5 represents halogen or C1-3alkyl; V represents NR3, S or O; R3 represents hydrogen or C1-3alkyl; one of A1 and A2 represents N and the other represents CH; Each R4, R6, R7, R8, R9 independently represents hydrogen or C1-3alkyl; R10 represents hydrogen, -C1-6alkyl, -C1-3alkylCONRaRb, -C1-3alkylCO2C1-4alkyl, -CO2C1-4alkyl or -C1-3alkylCO2H; and pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compound(s) of formula (I), pharmaceutical compositions containing compound(s) of formula (I) and to the use of compound(s) of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.